Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Equity Average (2023 - 2026)

ADC Therapeutics has reported Equity Average over the past 4 years, most recently at -$201.1 million for Q1 2026.

  • Quarterly results put Equity Average at -$201.1 million for Q1 2026, up 8.77% from a year ago — trailing twelve months through Mar 2026 was -$201.1 million (up 8.77% YoY), and the annual figure for FY2025 was -$194.2 million, down 10.71%.
  • Equity Average reached -$201.1 million in Q1 2026 per ADCT's latest filing, up from -$212.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $18.1 million in Q1 2023 and bottomed at -$220.4 million in Q1 2025.
  • Median Equity Average over the past 4 years was -$171.3 million (2024), compared with a mean of -$143.9 million.
  • The largest annual shift saw Equity Average crashed 3837.33% in 2024 before it increased 8.77% in 2026.
  • Over 4 years, Equity Average stood at -$106.2 million in 2023, then plummeted by 76.28% to -$187.3 million in 2024, then fell by 13.2% to -$212.0 million in 2025, then rose by 5.14% to -$201.1 million in 2026.
  • Business Quant data shows Equity Average for ADCT at -$201.1 million in Q1 2026, -$212.0 million in Q4 2025, and -$218.7 million in Q3 2025.